Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-301: Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression
2023-505455-44-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 2, open-label, single-arm trial of bemarituzumab in head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), intrahepatic cholangiocarcinoma (ICC) and 7 more, sponsored by Amgen. Primary endpoints: Dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in vital signs, visual acuity, and clinical laboratory tests… and Objective response (OR) (Phase 2). Started Jun 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)intrahepatic cholangiocarcinoma (ICC)Non-small cell lung cancer adenocarcinoma (NSCLC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2023-505455-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505455-44-00.